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Objective: Cigarette smoking is associated with reduced pulmonary function and increased risk factors
for cardiovascular disease. This randomized placebo-controlled double-blind study evaluated the effects of two
different combinations of mixed fruit and vegetable juice powder concentrate (Juice Plus+ , NSA, Collierville,
TN) on heavy smokers.
Methods: At baseline (T0) and after 3 months’ supplementation (T1), pulmonary function parameters and
cardiovascular risk factors—that is, plasma total homocysteine (tHcy) with related B vitamins and cysteine (tCys)
concentrations—were assessed in 75 apparently healthy smokers (aged 49.2 ± 10.6 years, >20 cigarettes/d,
duration ≥10 years) randomized into 3 groups: placebo (P), fruit/vegetable (FV) and fruit/vegetable/berry (FVB).
Results: T0: most smokers showed abnormalities in tHcy and tCys concentrations. T1: respiratory function
was unchanged in P and slightly, but not significantly, improved in FV, whereas FVB showed a significant
improvement in forced expiratory flow at 25% (FEF25; p < 0.0001 vs P and FV) and significant improvement in
CO diffusion lung/alveolar volume (DLCO/VA). FV and FVB (50%) showed significant reduction in tHcy and
tCys compared to T0 ( p < 0.0001) and P ( p < 0.0001).
Conclusions: At T1, both supplemented groups, but to a greater extent the FVB group, showed improvements
in some pulmonary parameters, cardiovascular risk factors, and folate status. The beneficial effects of Juice Plus+
supplementation could potentially help smokers, even if smoking cessation is advisable.
INTRODUCTION
Smokers are self-exposed to inhaled toxic molecules con-
tained in tobacco smoke [1]. Habitual smoking is independently
Address correspondence to: Fabrizia Bamonti, Dipartimento Scienze Mediche, Universita` degli Studi di Milano, Fondazione IRCCS Ca’ Granda Ospedale Maggiore
Policlinico, via F. Sforza 35, 20122 Milan, ITALY. E-mail: fabrizia.bamonti@unimi.it
The study was supported in part by a grant from NSA, LLC.
Abbreviations: BMI = body mass index, B12 = vitamin B12, CBC = complete blood count, Cys = cysteine, DLCO/VA = CO diffusion lung per unit alveolar volume, EDTA
= ethylenediaminetetraacetic acid, Ery-Fol = erythrocyte folate, FEF25 = forced expiratory flow at 25% of forced vital capacity, FEF50 = forced expiratory flow at 50% of
forced vital capacity, FEF75 = forced expiratory flow at 75% of forced vital capacity, FEV1 = forced expiratory volume in 1 second, FVC = forced vital capacity, Hcy =
homocysteine, HoloTC = holotranscobalamin, NAC = N-acetylcysteine, PEF = peak expiratory flow, RONS = reactive oxygen and nitrogen species, S-Fol = serum folate.
associated with hyperhomocysteinemia [2] and oxidative stress
[3] and is related to the progression of atherosclerotic lesions
[2]. Moreover, a relationship between smoking and a high
risk of developing reduced pulmonary function and other
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Nutraceutics’ Effects on Cigarette Smoking Damage
chronic obstructive pulmonary conditions has been reported
[4].
Lung exposure to reactive oxygen and nitrogen species
(RONS) production is greatly increased by smoking, with a
resulting antioxidant imbalance, cellular biochemical changes,
damage to lung parenchyma, and increasing need for antioxi-
dant nutrients [5]. Airway epithelial mucus cell hyperplasia and
decreased cilia and ciliary beat frequency precede changes in
pulmonary function [6]. Tobacco smoking may influence plasma
total homocysteine (tHcy) and total cysteine (tCys) concentra-
tions [7, 8]; redox changes in these aminothiols may partially
explain the adverse influence of tobacco on long-term health
[9]. Hyperhomocysteinemia and associated changes in cysteine
have been reported in patients with cardiovascular disease [10].
El-Khairy et al. demonstrated a U-shaped relationship between
plasma tCys and cardiovascular disease (with the highest risk at
the lowest and highest values and the desirable reference inter-
val as mid-range of values) [11]. The interplay between different
aminothiols may have an important role in protecting and repair-
ing oxidative damage [12].
Smokers’ lifestyles are different from nonsmokers’ lifestyles
in that smokers consume less fruit and vegetables and there-
fore could have lower antioxidant capacity from diet alone [2,
13]. Many fruit and vegetable components function as antioxi-
dants and neutralize RONS [14]. Moreover, whole fruits and/or
vegetables may be biologically more effective than synthetic
compounds given as supplements [5].
If diet-derived antioxidants are protective against oxidative
damage, smokers’ low dietary intake of plant foods could con-
tribute to suboptimal lung function and increase respiratory mor-
bidity [13]. Because lasting dietary change has proven difficult
to achieve, a supplement designed to provide natural nutrients
from fruits and vegetables, such as Juice Plus+ (NSA, Col-
lierville, TN) may help control RONS activity when added to
the habitual diet of heavy smokers.
Juice Plus+ supplement, composed primarily of fruit and
vegetable juice powder concentrate, contains several antioxi-
dant compounds (vitamins C and E, folate, and flavonoids).
Walda et al. [15] have shown the protective effects of fruit con-
taining polyphenols and vitamin E against chronic inflamma-
tory diseases. The beneficial effects of Juice Plus+ intervention
were reported by Samman et al. [16] and Kiefer et al. [17] us-
ing different regimens (dosage, duration, subjects). Increased
plasma levels of important antioxidant nutrients were found in
two crossover trials: 2 periods of 6 weeks separated by a 3-week
wash-out with smokers and nonsmokers [16] and a total period of
14 weeks (crossover week 7) with healthy men and women [17].
Moreover, as previously reported, Juice Plus+ supplement
reduces tHcy levels [16, 18, 19] and oxidative stress markers
[20–22] and increases beta-carotene [21] and folate concentra-
tions [18].
The first Juice Plus+ commercial product, tested previously
[16, 17, 20], was supplied by the factory with a newer berry prod-
uct (Juice Plus+ Vineyard) and any added effects were thereafter
investigated. In our first paper [20], we evaluated the beneficial
effects of one month Juice Plus+ on light smokers; in our second
study [23] we evaluated the effects of 3 months of Juice Plus+
alone or with added Juice Plus+ Vineyard compared to placebo
on heavy smokers without known respiratory complications. In
both studies we observed a significant decrease in plasma free
malondialdehyde (f-MDA, an index of recent lipid peroxidation)
concentrations using the gas chromatography–mass spectrom-
etry reference method (with dideuterated MDA as an isotopic
internal standard) [24]. After consumption of both Juice Plus+
formulations, Jin et al. [25] reported increased superoxide dis-
mutase concentrations and reduced markers of chronic systemic
inflammation in healthy adults.
In our second randomized double-blind placebo-controlled
study, after 3 months’ nutraceutical supplementation, we found a
significant improvement in some oxidative alterations attributed
to long-term cigarette smoking [23]. Therefore, the aim of this
ancillary study was to evaluate the effects of 3 months’ sup-
plementation with the two different formulations (Juice Plus+
and Juice Plus+ Vineyard) on heavy smokers’ pulmonary func-
tion and cardiovascular risk factors (i.e., plasma tHcy and tCys).
Moreover, the status of the Hcy metabolically related vitamins—
that is, serum and erythrocyte folate, vitamin B12, and its bio-
logically active form holotranscobalamin—was assessed.
METHODS
Subjects
Eligible participants were apparently healthy current heavy
smokers who reported a smoking history of 20 or more cigarettes
per day for at least 10 years without respiratory complications
detected on spirometric examination. Exclusion criteria included
a history of chronic or current health conditions or unstable psy-
chiatric disorders and alcohol abuse, body mass index (BMI) <
19 or BMI > 25 kg/m2, pregnancy, lactation, use of long term
medication, or regular vitamin supplementation. During an ini-
tial screening visit, all participants provided written informed
consent and were then interviewed about general health, habit-
ual dietary intake, lifestyle, and smoking habits. This report is of
a subpopulation of the most compliant smokers reported in our
previous study [23] (75 volunteers: 46 men, 29 women, mean
age 49.2 ± 10.6 years). They were recruited at two Milan hospi-
tals (Dipartimento Pneumologia, Ospedale Niguarda and Clinica
del Lavoro “Devoto”, Ospedale Maggiore Policlinico). Eligibil-
ity was evaluated by standard routine examinations including
complete blood count (CBC) and lipid panel. This study was
conducted according to the Declaration of Helsinki guidelines
for Research on Human Subjects and was approved by both Hu-
man Ethic Committees of the “San Giuseppe e Sacra Famiglia”
Ospedale, Erba, Italy (Registration number 27/05/CE/smc), and
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Nutraceutics’ Effects on Cigarette Smoking Damage
Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico,
Milan, Italy (Registration number 2552). All participants were
asked to maintain the same lifestyle, diet, and daily smoking
habits for the 3-month study period.
Study Design
As described previously [23], subjects were randomly di-
vided into 3 groups. In this double-blind placebo-controlled an-
cillary study the number of subjects was uneven: some initially
enrolled and then chose not to participate and therefore were not
included in the analysis.
• Placebo (P: 25 subjects, 15 men, 10 women, mean age
51.4 ± 12 years)
• Blended fruit and vegetable juice concentrate powder (FV: 26
subjects, 16 men, 10 women, mean age 46.6 ± 7.9 years)
• FV as described above with additional grape and berry juice
concentrate powder ingredients (FVB: 24 subjects, 15 men,
9 women, mean age 49.9 ± 11.4 years)
The FV capsules contained primarily fruit and vegetable
juice powder concentrate from apple, beet, broccoli, cabbage,
carrot, cherry (acerola), cranberry, kale, orange, peach, papaya,
parsley, pineapple, spinach, tomato and provided 7.5 mg beta-
carotene, 234 mg vitamin C, 32 mg vitamin E, and 420 μg folate
(42 kJ/day) [21, 22]. The FVB capsules additionally contained
berry juice powder from bilberry, blackberry, black currant, blue-
berry, cranberry, elderberry, grape (Concord), raspberry, red cur-
rant and provided 7.5 mg beta-carotene, 200 mg vitamin C,
60 mg vitamin E, and 600 μg folate (63 kJ/day) [22]. All sub-
jects were instructed to take their assigned capsules twice daily
with meals (3 in the morning and 3 in the evening) for 3 months
while following their habitual diet and lifestyle.
These capsules contained all placebo powder; a blend of
the equivalent of 2 fruit capsules, 2 vegetable capsules, and 2
placebo capsules; or a blend equivalent to 2 fruit, 2 vegetable,
and 2 berry capsules. To keep the study blinded, the placebo
capsules were identical in appearance and contained primarily
microcrystalline cellulose. Capsules were provided in opaque
gelatin shells by the study sponsor and packaged in identical
and unlabeled bottles. All of the capsules were tested for ac-
curate potency by capsule assignment group. All capsules were
replaced with a fresh supply prior to the 2-year expiration date.
The sealed bottles of capsules were marked with assigned ran-
dom numbers at the factory. All subjects regularly consumed
a Mediterranean diet. Dietary intake assessment was checked
at baseline (T0) using the “Nutrition Status Assessment Score”
questionnaire [26], which listed a number of items, such as num-
ber of cigarettes, use of alcohol, physical activity, and intake of
ordinary Italian foods [23, 26]. The protocol directions were as-
sessed by all participants by a daily diary returned to clinicians
after 3 months’ supplementation (T1).
Compliance with lifestyle and study protocol was checked
by weekly phone calls and by counting returned capsules at T1.
Spirometric Parameters
At T0 and at T1 pulmonary function was measured with
an electronic flow volume spirometer V-max 22 with Autobox
(SensorMedics, Milan, Italy) according to European Respiratory
Society/American Thoracic Society guidelines (ERS ATS 2005)
[27]. The following spirometry indexes were measured: forced
expiratory volume in 1 second (FEV1); forced expiratory flow
at 25%, 50%, 75% forced vital capacity (FEF25, FEF50, FEF75);
CO diffusion lung per unit of alveolar volume (DLCO/VA),
forced vital capacity (FVC); all parameters are reported as Ac-
tual/Expected %. The actual Tiffeneau index is the FEV1/FVC
ratio, where FVC is the maximum amount of air anyone can
expel from the lungs after maximum inspiration. According to
Global Initiative for Chronic Obstructive Lung Disease (GOLD)
guidelines [28], subjects were not eligible for this study if their
actual Tiffeneau index was less than 0.7 and/or less than 88%
of expected value (expected normal values are calculated by
spirometer, accounting for several factors; i.e., age, sex, height,
weight, ethnicity). The use of the Tiffeneau index is recom-
mended by GOLD guidelines [28] as an early sensitive indicator
of airway obstruction and helps to differentiate air flow limita-
tions from restrictive abnormalities. All subjects were without
respiratory complications and had at least 3 consecutive forced
expiratory tests (5% intra-individual variation among the 3 val-
ues is accepted): the best peak expiratory flow was chosen as each
subject’s personal index according to ERS ATS 2005 guidelines
[27]. The highest peak expiratory flow value is indicative of the
highest forced expiration. Smoking status was not assessed by
measuring urinary cotinine concentrations at T0 and T1 because
several factors affecting the cotinine results of the smokers might
lead to inaccurate evaluations, especially when the assessment
of personal exposure to tobacco smoke is based on self-reports.
Blood Samples
At T0 and T1, blood specimens from fasting subjects were
collected in light-protected tubes, either without additives for
serum folate (S-Fol), vitamin B12 (B12), and holotranscobalamin
(HoloTC) measurements or with EDTA to prevent coagulation
for CBC, erythrocyte folate (Ery-Fol), and tHcy and tCys anal-
ysis. A specimen of whole blood with EDTA was immediately
centrifuged for total Hcy and Cys measurement, aliquoted, and
immediately frozen on liquid nitrogen and stored at −80◦C. T0
and T1 serum and whole blood samples were frozen and stored
at −80◦C for batch analysis at the end of the study.
Analytical and Biochemical Analysis
The CBC was performed as routine samples at the study hos-
pitals. Serum B12 and HoloTC concentrations were determined
20 VOL. 32, NO. 1
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Nutraceutics’ Effects on Cigarette Smoking Damage
Table 1. Demographic and Baseline (T0) Biochemical Characteristics of 75 Compliant Smokers
Reference Interval or
Cut-Off Values P Group (n = 25) FV Group (n = 26) FVB Group (n = 24) p
Men/women — 15/10 16/10 15/9 NS
Age (years) — 51.4 ± 12 46.6 ± 7.9 49.9 ± 11.4 NS
Number of cigarettes (daily) — 31.2 ± 15.3 25.9 ± 8.7 25 ± 12 NS
Duration of smoking (years) — 24.4 ± 3.9 23.5 ± 2.4 25.7 ± 11.1 NS
Analyte
BMI (18–25 Kg/m2) 23.0 ± 3.2 23.3 ± 1.9 22.7 ± 2.5 NS
WBC (4–10 109/L) 7.9 ± 1.2 8.9 ± 2.5 8.2 ± 2.3 NS
RBC (4.1–5.1 1012/L) 4.9 ± 0.5 5.2 ± 0.8 4.9 ± 0.5 NS
Hb (12–16 g/dL) 15.1 ± 1.4 14.8 ± 1.9 15.0 ± 1.8 NS
MCV (78–99 fL) 87.6 ± 19.4 87.0 ± 9.6 91.7 ± 6.9 NS
tHcy (<10 μmol/L) 11.5 ± 6.6 (52%) 12.3 ± 7.8 (57%) 10.8 ± 7.4 (38%) NS
tCys (250–275 μmol/L) 280 ± 63.8 (76%) 245.3 ± 65.1 (92%) 247.9 ± 75.9 (76%) NS
S-Fol (7–28 nmol/L) 13.9 ± 5.4 (0%) 13.7 ± 6.7 (1%) 15.7 ± 7.7 (3.1%) NS
Ery-Fol (421–1462 mol/L) 471.2 ± 117.2 (33%) 534.5 ± 170.1 (35%) 603.5 ± 341.6 (25%) NS
Vitamin B12 (164–835 pmol/L) 269 ± 85.4 (3%) 281 ± 84.6 (8%) 289 ± 95.1 (7%) NS
HoloTC (>40 pmol/L) 60.2 ± 23.0 (22%) 63.9 ± 18.9 (15%) 64.1 ± 23.1 (10%) NS
Data are expressed as mean ± SD. (%) = % of subjects with values outside of the reference interval or cutoff.
P = placebo, FV = fruit/vegetable, FVB = fruit/vegetable/berry, NS = nonsignificant, BMI = body mass index, WBC = white blood cells, RBC = red blood cells, Hb
= hemoglobin, MCV = mean corpuscular volume, tHcy = total homocysteine, tCys = total cysteine, S-Fol = serum folate, Ery-Fol = erythrocyte folate, HoloTC =
holotranscobalamin.
by commercial immunoenzymatic assays (AxSYM B12 and
AxSYM Active-B12, respectively) on the automated AxSYM
analyzer (Abbott Diagnostics, Abbott Park, IL), as previously
reported [29, 30]. S-Fol and Ery-Fol concentrations were deter-
mined by commercial immunoenzymatic assay (AxSYM Folate)
as previously described [31]. Plasma tHcy and tCys concentra-
tions were measured using high-performance liquid chromatog-
raphy with fluorescence detection (ProStar, Varian, Surrey, UK)
as previously reported [32]. Briefly, EDTA plasma (100 μL)
was treated with a 10% tri-n-butylphosphine in dimethylfor-
mamide solution (10 μL) for 30 minutes at 4◦C in order to re-
duce the oxidized thiols and release them from plasma proteins.
One hundred microliters of 10% trichloroacetic acid containing
1 mmol/L EDTA was added, mixed, and centrifuged (10,000 g, 2
minutes) to remove precipitated proteins. The clear supernatant
(100 μL) was mixed with dimethylformamide (5 μL), 1 mol/L
borate buffer (100 μL, pH 11) containing 4 mmol/L EDTA,
1.55 mol/L NaOH (10 μL), and ammonium-7-fluoro-benzo-2-
oxa-1,3-diazole-4-sulfonate (10 μL) as a derivatizing reagent.
The mixture was incubated for 60 minutes at 60◦C before high-
performance liquid chromatography analysis. Both tHcy and
tCys concentrations include oxidized (disulfides), conjugated
(protein-bound), and reduced free Hcy and Cys.
Statistical Analysis
Continuous variables are reported as mean ± SD. The differ-
ences between groups were evaluated by t test for independent
samples and by analysis of variance. Follow-up differences in
each group were evaluated by t test for paired samples. Statistical
significance was assigned as a p value < 0.05. Statistical anal-
yses were performed using R statistical Software (Revolution
Analytics, Palo Alto, CA).
RESULTS
This ancillary project included 75 participants (46 men, 29
women, mean age 49.2 ± 10.6) who were >95% protocol
compliant and completed the 3-month study. As shown in
Table 1, at baseline no statistical differences in demographic and
biochemical characteristics were found between the 3 random-
ized groups. Women had approximately the same mean age as
men (49.0 ± 10.3 vs 49.4 ± 11.0 years, respectively; p = NS)
but a significantly lower BMI (22.0 ± 3.0 vs 24.0 ± 1.5 kg/m2,
respectively; p = 0.001) than men. At baseline, all groups had a
normal hematological status and similar levels of tHcy and tCys.
However, on average 50% of smokers had mild hyperhomo-
cysteinemia and most subjects had tCys concentrations either
above or below the reference interval. With regard to folate, on
average 31% of subjects had Ery-Fol concentrations below the
reference interval, although few subjects had S-Fol levels below
the reference interval. With regard to B12 status, on average
6% of subjects’ B12 concentrations were below the reference
interval, and on average 15% of subjects’ HoloTC levels were
below the cutoff. As shown in Table 2, at baseline there were no
significant differences in respiratory parameters between the 3
randomized groups. After 3 months’ supplementation (Table 3),
the FV group’s FEF25 differences between T1 and T0 values
(expressed as mean delta) improved slightly compared to the P
group’s, whereas the FVB group’s FEF25 differences improved
significantly compared to the P group (p < 0.0001) and the FV
JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION 21
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Table 2. Baseline (T0) Pulmonary Parameters of 75 Compliant Smokers
Pulmonary function P group (n = 25) FV group (n = 26) FVB group (n = 24) p
FEV1 (%) 98.2 ± 12.3 102.2 ± 13.2 99.2 ± 14.0 NS
FEF25 (%) 96.4 ± 20.2 104.4 ± 26.1 97.1 ± 29.4 NS
DLCO/VA (%) 79.5 ± 14.3 82.0 ± 18.1 75.4 ± 10.7 NS
FVC (%) 102 ± 24.9 109 ± 16.2 106.2 ± 12.6 NS
Tiffeneau index (%) 91.7 ± 9.1 95.2 ± 7.3 93 ± 9 NS
Data are expressed as mean ± SD and refer to Actual/Expected %. P = placebo, FV = fruit/vegetable, FVB = fruit/vegetable/berry, NS = nonsignificant, FEV1 = forced
expiratory volume in 1 second, FEF25 = forced expiratory flow at 25% of forced vital capacity, DLCO/VA = CO diffusion lung per unit alveolar volume, FVC = forced
volume capacity, Tiffeneau Index (FEV1/FVC)% = index of air-flow obstruction.
group (p < 0.001). The FV group’s (p < 0.05) and FVB group’s
(p < 0.001) DLCO/VA values improved significantly compared
to the P group’s. Both supplemented groups’ FEV1 mean delta
values improved, even if not significantly so, whereas the P
group’s FEV1 values were negative. By comparison, the P
group’s respiratory function deteriorated slightly. As shown
in Table 3, both FV and FVB groups’, but not P group’s,
tHcy levels decreased significantly (p < 0.0001 vs T0 and p
< 0.001 vs P). Both FV and FVB groups’, but not P group’s,
tCys concentrations improved significantly. On average, 50% of
supplemented smokers’ tCys concentrations normalized (p <
0.0001 vs P). At T1 both nutraceutical groups’ S-Fol and Ery-Fol
concentrations increased significantly, whereas, as expected,
vitamin B12 and HoloTC levels were unchanged (data not
shown). Analysis of variance, used to compare the differences
between groups, showed the same p values as the t test.
DISCUSSION
After only 3 months’ supplementation with two different
formulations of encapsulated fruit and vegetable juice powder
concentrate, heavy smokers without existing respiratory com-
plications showed significant improvement in some respiratory
function markers and in folate status, in addition to normalized
values of the cardiovascular risk factors (i.e., plasma tHcy and
tCys). Placebo subjects did not show any change from baseline
values. Smokers’ smallest airways are the first impacted; inflam-
mation at first can reduce respiratory function and then lead to
chronic obstructive pulmonary changes [6, 33]. FEV1, an index
predominantly related to the function of middle size and larger
airways, has been reported to take one year to develop (depend-
ing on factors such as intensity and duration of cigarette smok-
ing) and is indicative of deep pulmonary exposure and damage
Table 3. Pulmonary and Biochemical Parameters of 75 Compliant Smokers at the End of the Study (T1) and Differences (Mean )
between T1 and T0 Values after 3 Months’ Supplementation
P group (n = 25) FV group (n = 26) FVB group (n = 24)
Parameter T1 T1−T0 T1 T1−T0 T1 T1−T0
FEV1 (%) 97.7 ± 17.1 −0.67 ± 3.46 102.8 ± 13.2 0.41 ± 4.66 99.4 ± 12.1 0.2 ± 4.15
FEF25 (%) 89.5 ± 10.9 −6.50 ± 4.2 101.1 ± 15.2 −3.2 ± 5.6# 98.6 ± 4.9 1.9 ± 3.6
DLCO/VA (%) 75.2 ± 8.62 −5.22 ± 12.9 80.3 ± 2.4∗ 0.46 ± 3.10∗ 80.9 ± 1.79∗ 5.1 ± 4.96
FVC (%) 101.6 ± 19.3 −0.7 ± 8.4 110 ± 13.4 1.1 ± 5.8 107.1 ± 11.3 1.2 ± 6.7
Tiffeneau index (%) 89.3 ± 17.3 −2.17 ± 10.2 96.2 ± 13.1 0.9 ± 7.4 93.8 ± 12.4 0.6 ± 6.2
tHcy (μmol/L) 11.4 ± 5.9 −0.07 ± 1.5 9.4 ± 6.3 −2.8 ± 2.3 8.1 ± 3.5 −2.9 ± 5.4
(48%) (26%) (24%)
tCys (μmol/L) 244.9 ± 56.7) −39.5 ± 36.2 260.6 ± 40.5 16.2 ± 38.4 258.3 ± 62.8 11.3 ± 42.3
(66%) (32%) (29%)
S-Fol (nmol/L) 16.0 ± 5.6 2.1 ± 5.6 27.8 ± 8.3 14.1 ± 8.6 31.8 ± 8.7 16.7 ± 8.8
(4%) (0%) (0%)
Ery-Fol (nmol/L) 625 ± 107 153 ± 112 (4%) 1062 ± 331 527 ± 356 (0%) 1199 ± 395 622 ± 321 (0%)
(4%) (0%) (0%)
Data are expressed as mean ± SD and refer to Actual/Expected %. (%) = Percentage of subjects with values out of reference interval or cutoff.
∗p < 0.05 vs P, p < 0.001 vs P, p < 0.0001 vs P, #p < 0.001 vs FVB.
P = placebo, FV = fruit/vegetable, FVB = fruit/vegetable/berry, FEV1 = forced expiratory volume in 1 second, FEF25 = forced expiratory flow at 25% of forced vital
capacity, DLCO/VA = CO diffusion lung per unit alveolar volume, FVC = forced volume capacity, tHcy = total homocysteine, tCys = total cysteine, S-Fol = serum folate,
Ery-Fol = erythrocyte folate, Tiffeneau Index (FEV1/FVC)% = index of air-flow obstruction.
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[6, 34]. In contrast, changes in FEF25 (an index predominantly
related to small size pulmonary airways) can reveal an early
bronchiolar damage and may improve faster than FEV1. The
FEV1/FVC ratio, also called the Tiffeneau index, is a calculated
ratio used in the diagnosis of obstructive and lung disease [35].
The significant increase in the DLCO/VA value may be due
to a reduction of bronchiolar wall inflammation status and/or
blood microcirculation leading to the increased FEF25 index.
In our subjects, not all pulmonary markers improved after the
interventions. In fact, FEV1 and the Tiffeneau index did not sig-
nificantly improve in either phytonutrient group, whereas FEF25
and DLCO/VA significantly improved in both of these groups
and to a greater degree in the FVB group. This may be an in-
dicative result of increased dietary antioxidants provided by the
FV and (even more) the FVB capsules during the relatively short
study period. The placebo group did not show any improvement.
Cigarette smoke is known to induce mucus hypersecretion and
nonproductive cough. Interestingly, at T1, an increase in produc-
tive morning cough was subjectively reported by 19 FV and FVB
subjects. The reduction of mucus viscosity and the widening of
the smaller airways (documented by improved FEF25) may ex-
plain increased expectoration and hence increased productive
cough. No difference in respiratory function was observed in
the P group but 50% showed worsening respiratory function,
possibly due to seasonal factors (i.e., bronchitis, allergies). Our
findings were in agreement with the study by Roll et al., which
reported a reduction in common cold symptoms using the same
FV supplement for 8 months, including a 2-month run-in period
[36]. The presence of biologically important thiols has been re-
ported in several fruits and vegetables, with content depending
on various storage and cooking conditions [37]. Bioflavonoids
have both antioxidant and anti-inflammatory properties and may
also contribute to the smokers’ improved respiratory function.
Flavonoids have reported anti-inflammatory effects attributed to
inhibition of lipoxygenase and cyclooxigenase, which are in-
volved in the formation of pro-inflammatory factors (such as
prostaglandins and leukotrienes), leading to pulmonary patho-
genesis [38]. A study by Tabak et al. showed a positive as-
sociation between flavonoid intake and FEV1 increase [39].
Our results are in agreement with the study by Walda et al.,
which reported the protective effect of fruit containing polyphe-
nols and vitamin E against chronic inflammatory diseases [15],
and the study by Jin et al., which showed reduced markers of
chronic systemic inflammation in healthy adults taking the same
FV and FVB encapsulated juice concentrate [25]. Moreover,
the improvement in respiratory functions due to the antioxi-
dant properties of the FV and FVB capsules can be related to
both the decrease in plasma free malondialdehyde (an indicator
of recent lipid peroxidation) and reduced oxidized low-density
lipoproteins, as we have previously reported on these same heavy
smokers [23].
Although following a Mediterranean diet, some subjects had
a suboptimal baseline HoloTC and Ery-Fol status, in agreement
with Tungtrongchitr et al. [40]. At baseline, on average 15% of
subjects had low levels of HoloTC (Table 1). The determination
of cobalamin status by measuring the HoloTC concentrations
represents a new approach for diagnosing subtle cobalamin de-
ficiency. HoloTC, the biologically active form of vitamin B12,
is considered the earliest and most sensitive marker of vitamin
B12 deficiency [30]. Adequate folate and vitamin B12 levels are
necessary for cellular metabolism, whereas insufficiency is as-
sociated with several disorders [41–43]. Ery-Fol concentration
is a reliable indicator of long-term folate status and general di-
etary intake, and S-Fol indicates more recent intake [44]. A more
comprehensive estimate of total folate status is provided by as-
sessing both parameters, as we did in this and previous studies
[44, 45]. Several mechanisms (decreased dietary intake, reduced
absorption, diminished hepatic uptake, increased urinary excre-
tion) may explain folate deficiency in smokers [40]. However,
in agreement with the European Concerted Action Project, a
possible interaction between chemical components of cigarette
smoke and folate coenzymes [46] could lower folate status and
promote hyperhomocysteinemia [40], increasing the risk of car-
diovascular diseases [47]. In this study, though almost all the
smokers had adequate S-Fol levels, about 30% of subjects had
baseline suboptimal Ery-Fol concentrations (Table 1). After 3
months of either FV or FVB supplementation, S-Fol and Ery-
Fol levels increased significantly (p < 0.001 and p < 0.0001,
respectively) compared to subjects in the P group and, interest-
ingly, the majority of Ery-Fol values were within the reference
interval. This finding is in agreement with previous studies using
the FV capsules [16, 18, 19]. Both formulations (Juice Plus+
and Juice Plus+ Vineyard) only influenced folate status, as ex-
pected. With regards to tHcy and tCys levels, at baseline more
than 50% of our smokers suffered from mild hyperhomocys-
teinemia and most of smokers showed tCys levels outside the
reference interval. After 3 months’ supplementation, only FV
and FVB groups’ total homocysteine levels decreased signif-
icantly (p < 0.0001), and tCys levels normalized (reference
interval, 250–275 μmol/L) in a higher percentage of smokers
compared to baseline. According to other authors [10, 11], tHcy
and tCys levels could be considered intercorrelated cardiovascu-
lar risk factors. Our findings support these hypotheses because,
after a 3-month supplementation, most of the smokers in this
study who were assigned the FV and FVB capsules showed
an improvement in respiratory function and in both tHcy and
tCys concentrations. Sobczak et al. [7] evaluated the influence
of smoking on plasma tHcy and tCys levels and reported that this
is a strong determinant only of plasma tHcy but not tCys levels.
Cysteine is thought to be the limiting amino acid for glu-
tathione synthesis. Glutathione is an important component of the
endogenous antioxidant system. We speculate that the improved
cysteine levels may help explain the mucolitic effect reported
by 19 of the FV and FVB subjects. In fact, N-acetylcysteine is
a glutathione precursor and a mucolytic compound with antiox-
idant and anti-inflammatory properties. These N-acetylcysteine
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mucolytic properties are due to disruption of disulfide bridges in
mucoprotein macromolecules, thus decreasing mucus viscosity,
and its biotransformation to cysteine is better absorbed when
mixed with vitamins and flavonoids [48]. This is an interesting
hypothesis; however, our study did not deal with the potential
underlying mechanisms due to the number of components con-
tained in fruit and vegetables. Additional research is necessary
to confirm these findings.
In conclusion, the pulmonary function and biochemical
parameters of the healthy heavy smokers assigned to the FV
and FVB capsules seemed to have beneficial effects from
the nutraceutical treatment. It appears that there was a partial
reduction in some of the damaging effects of smoking cigarettes.
These findings could be related to the significant improvement
in some oxidative alterations previously reported [23] and could
suggest a potential use of nutraceutical treatment to reduce
some smoking-related complications.
Finally, even if the beneficial effects of intervention with nu-
traceutical formulations could encourage further investigations,
this cannot substitute for smoking cessation.
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